**Abstract**

GPR52 is an orphan G protein-coupled receptor which is mainly expressed in the brain and shows a unique co-expression profile. In the striatum it is expressed almost exclusively in neurons also expressing D2-like dopamine receptors, whereas in the cortex it mainly co-expresses with the D1-like dopamine receptor. Because GPR52 is Gs-coupled, this has led to the prediction that agonists of GPR52 may have both antipsychotic and pro-cognitive properties by their action in the striatum and the prefrontal cortex, respectively. This makes GPR52 a particularly interesting target for the treatment of schizophrenia. While tool compounds have, indeed, been shown to reverse pharmacologically induced striatal hyperdopaminergic states, direct evidence for their efficacy in cognition was lacking. Here, we show data from *in vitro*, *ex vivo* and *in vivo* studies strongly supporting the hypothesized pro-cognitive efficacy.

Tool compounds were synthesized following Takeda patents WO2010/018874, WO2011/093352 and WO2012/020738 and their *in vitro* efficacy was confirmed in stably transfected HEK cells. The compounds led to a robust increase of intracellular cAMP concentrations, with an EC50 of 30 nM for the tool compound chosen for further characterization. To test the hypothesis that this increase in cAMP affects synaptic transmission in the prefrontal cortex, layer V responses to layer II stimulation were measured in prefrontal cortical rat brain slices. Bath application of the tool compound led to a robust and sustained increase in excitatory post-synaptic potentials, suggesting the possibility of pro-cognitive efficacy. To test this, working memory performance was measured in mice in the T-maze spontaneous alternation task. The deficit induced by the NMDA receptor antagonist MK-801 was dose-dependently reversed by the administration of the GPR52 tool compound agonist.

Together, these data show that GPR52 agonists also have potential for treatment of cognitive symptoms in psychiatric disorders characterized by cortical dopaminergic or glutamatergic hypofunction, such as schizophrenia.
